Trial Profile

Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Cisplatin (Primary) ; Nedaplatin (Primary) ; Paclitaxel (Primary) ; Tislelizumab (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms PPIO-004-EC001

Most Recent Events

04 Jun 2024 Results(n=62) exploring potential biomarkers in treatment of locally advanced ESCC with tislelizumab combined with chemotherapy preoperatively , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
09 Jan 2024 Status changed from not yet recruiting to recruiting.
09 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Feb 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com